D Brock Hewitt1, Yaming Li1, Oindrila Bhattacharyya2,3, James L Fisher4, Daniel Stover5, Samilia Obeng-Gyasi6. 1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, N924 Doan Hall 410 West 10th, Columbus, OH, USA. 2. Department of Economics, Indiana University Purdue University, Indianapolis, IN, USA. 3. The William Tierney Center for Health Services Research, Regenstrief Institute, Inc., Indianapolis, IN, USA. 4. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA. 5. Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 6. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, N924 Doan Hall 410 West 10th, Columbus, OH, USA. Samilia.Obeng-Gyasi@osumc.edu.
Abstract
INTRODUCTION: Significant racial and ethnic disparities exist in breast cancer treatment and survival. However, studies characterizing these disparities among patients developing bilateral breast cancers (BBC) are lacking. The purpose of this study is to understand the association between race and ethnicity, sociodemographic factors, clinical variables, treatment, and mortality in patients with BBC--synchronous bilateral breast cancer (sBBC) or metachronous bilateral breast cancer (mBBC). METHODS: Patients diagnosed with mBBC or sBBC in the Surveillance, Epidemiology, and End Results program between 2010 and 2016 were examined. sBBC was defined as contralateral breast cancer <1 year after the initial cancer diagnosis, and mBBC was contralateral cancer ≥1 year. Univariable analysis examined sociodemographic, clinical, and treatment variables. Kaplan-Meier curves and Cox regression models evaluated disease-specific mortality. RESULTS: Of the 11,493 patients that met inclusion criteria, 9575 (83.3%) had sBBC, and 1918 (16.7%) had mBBC. There were significant racial and ethnic differences in stage, tumor subtype, surgical management, and chemotherapy within sBBC and mBBC groups. On adjusted multivariate analysis of all BBC patients, Black race (HR 1.42; 95%CI 1.11-1.80; p<0.005; Ref White) was associated with a higher disease-specific mortality. Conversely, patients with mBBC had a 25% relative risk reduction in disease-specific mortality (HR 0.75; 95%CI 0.61-0.92; p<0.01) compared to sBBC. Subset analysis suggested Black Race modified the effect of sBBC on mortality (p<0.0001). CONCLUSIONS: Among patients with BBC, there are racial and ethnic disparities in clinical characteristics, treatment, and mortality. Future studies should focus on strategies to reduce these disparities.
INTRODUCTION: Significant racial and ethnic disparities exist in breast cancer treatment and survival. However, studies characterizing these disparities among patients developing bilateral breast cancers (BBC) are lacking. The purpose of this study is to understand the association between race and ethnicity, sociodemographic factors, clinical variables, treatment, and mortality in patients with BBC--synchronous bilateral breast cancer (sBBC) or metachronous bilateral breast cancer (mBBC). METHODS: Patients diagnosed with mBBC or sBBC in the Surveillance, Epidemiology, and End Results program between 2010 and 2016 were examined. sBBC was defined as contralateral breast cancer <1 year after the initial cancer diagnosis, and mBBC was contralateral cancer ≥1 year. Univariable analysis examined sociodemographic, clinical, and treatment variables. Kaplan-Meier curves and Cox regression models evaluated disease-specific mortality. RESULTS: Of the 11,493 patients that met inclusion criteria, 9575 (83.3%) had sBBC, and 1918 (16.7%) had mBBC. There were significant racial and ethnic differences in stage, tumor subtype, surgical management, and chemotherapy within sBBC and mBBC groups. On adjusted multivariate analysis of all BBC patients, Black race (HR 1.42; 95%CI 1.11-1.80; p<0.005; Ref White) was associated with a higher disease-specific mortality. Conversely, patients with mBBC had a 25% relative risk reduction in disease-specific mortality (HR 0.75; 95%CI 0.61-0.92; p<0.01) compared to sBBC. Subset analysis suggested Black Race modified the effect of sBBC on mortality (p<0.0001). CONCLUSIONS: Among patients with BBC, there are racial and ethnic disparities in clinical characteristics, treatment, and mortality. Future studies should focus on strategies to reduce these disparities.
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Jacqueline W Miller; Judith Lee Smith; A Blythe Ryerson; Thomas C Tucker; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Nadia Howlader; Lynn A G Ries; Angela B Mariotto; Marsha E Reichman; Jennifer Ruhl; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2010-10-11 Impact factor: 13.506
Authors: Mikael Hartman; Kamila Czene; Marie Reilly; Jan Adolfsson; Jonas Bergh; Hans-Olov Adami; Paul W Dickman; Per Hall Journal: J Clin Oncol Date: 2007-09-20 Impact factor: 44.544
Authors: Julia A Knight; Leslie Bernstein; Joan Largent; Marinela Capanu; Colin B Begg; Lene Mellemkjaer; Charles F Lynch; Kathleen E Malone; Anne S Reiner; Xiaolin Liang; Robert W Haile; John D Boice; Jonine L Bernstein Journal: Am J Epidemiol Date: 2009-02-11 Impact factor: 4.897
Authors: Kevin Chu Foy; James L Fisher; Maryam B Lustberg; Darrell M Gray; Cecilia R DeGraffinreid; Electra D Paskett Journal: NPJ Breast Cancer Date: 2018-03-20